Suppr超能文献

生物可吸收支架在股浅动脉中的作用。

Role of bioresorbable stents in the superficial femoral artery.

作者信息

Vermassen F, Bouckenooghe I, Moreels N, Goverde P, Schroe H

机构信息

Ghent University Hospital, Ghent, Belgium.

出版信息

J Cardiovasc Surg (Torino). 2013 Apr;54(2):225-34.

Abstract

Bioresorbable stents or scaffolds are a new technology in the treatment of coronary and peripheral vascular disease. Their goal is to provide adequate support to the dilated vessel segment for the time needed and to disappear through a controlled resorption process afterwards. Doing so they can offer the early advantages and avoid the late complications related to stent placement such as stent-induced restenosis, stent fracture and problems at reintervention. Although the first implantation dates from more than ten years ago, this technology is still in its infancy and experience is still being built up. Most studies till now have been performed in the coronary arteries although the superficial femoral artery is an equally appealing area of application. Bioresorbable scaffolds are made of resorbable polymers or metals with or without antiproliferative drug elution. Early experiences in coronary arteries as well as in other areas such as the superficial femoral artery (SFA) have shown the importance of the material that is used, the design of the device and the duration of the absorption process. They suggest that elution of an antiproliferative drug might be necessary to obtain clinically acceptable results. Although initial results are promising with some of the newer generation devices results of larger studies with longer follow-up are eagerly awaited to define the precise place of this new technology. This article gives an overview of the existing evidence, the available devices, the clinical studies that have been performed in different areas and the preliminary results of a large multicenter study with a bioresorbable stent in the SFA.

摘要

生物可吸收支架是治疗冠状动脉和外周血管疾病的一项新技术。其目标是在所需时间内为扩张的血管段提供足够支撑,随后通过可控的吸收过程消失。这样一来,它们可以带来早期优势,并避免与支架置入相关的晚期并发症,如支架诱导的再狭窄、支架断裂以及再次干预时出现的问题。尽管首次植入距今已有十多年,但这项技术仍处于起步阶段,经验仍在积累之中。迄今为止,大多数研究是在冠状动脉中进行的,不过股浅动脉同样是一个有吸引力的应用领域。生物可吸收支架由可吸收聚合物或金属制成,有或没有抗增殖药物洗脱功能。在冠状动脉以及其他区域(如股浅动脉)的早期经验表明了所用材料、器械设计以及吸收过程持续时间的重要性。这些经验表明,为了获得临床上可接受的结果,可能需要洗脱抗增殖药物。尽管一些新一代器械的初步结果很有前景,但人们急切期待更大规模、随访时间更长的研究结果,以确定这项新技术的确切地位。本文概述了现有证据、可用器械、在不同区域进行的临床研究以及一项关于股浅动脉生物可吸收支架的大型多中心研究的初步结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验